The present disclosure relates to a method of preparing a thin film composite layer immobilizing vesicles incorporating a transmembrane protein on a porous substrate membrane, comprising providing an aqueous solution comprising the vesicles and a di-amine or tri-amine compound, covering the surface of a porous support membrane with the aqueous solution, applying a hydrophobic solution comprising an acyl halide compound, and allowing the aqueous solution and the hydrophobic solution to perform an interfacial polymerization reaction to form the thin film composite layer.

The present invention relates to a transdermal nano-carrier and, more specifically, to a nano-carrier having a chitosan-based nano-sponge structure. According to the present invention, as a nano-carrier having enhanced transdermal delivery on the basis of a complex containing chitosan is provided, it is possible to effectively deliver drugs, cosmetic materials, etc. into the skin.

Dimer and monomer molecules according to general formulas (I) or (II) are useful as lipid switch molecules when incorporated into a membrane of a liposome.

##STR00001##

wherein R.sup.1 is a hydrophobic tail having at least 6 carbons and wherein R.sup.2 is selected from the group consisting of —NH.sub.2,

##STR00002##

wherein, for the dimer, the linker is a saturated carbon chain having 2 to 6 carbons or is a para-xylene linker; and when R.sup.2 is charged anions are present to render the charge neutral. These molecules can bind ATP or similar small phosphorylated molecules between R.sup.2 groups, which changes the shape of the molecule or the molecules orientation within the membrane thereby acting as a “switch” to release a therapeutic agent from the liposome.

A nanodrug particle includes alginate and a camptothecin compound. The camptothecin compound is grafted onto the alginate, and the alginate and the camptothecin compound self-assemble and form a nanosphere. The disclosure also provides a method for preparing a nanodrug particle; the method includes: modifying alginate to form alginate having amine groups; modifying a camptothecin compound to form a camptothecin compound having a carboxyl group; forming a camptothecin-alginate polymer by reacting the alginate having amine groups with the camptothecin compound having a carboxyl group, wherein the camptothecin-alginate polymer self-assembles in an aqueous solution and forms a nanosphere.

A nano composite material aiming at an acidic sealing zone in osteoclasts and a preparation method thereof are provided. The nano composite material aiming at the acidic sealing zone in the osteoclasts includes a nano material, bone-targeting molecules, and a compound able to react with the acidic sealing zone in the osteoclasts, wherein: after being modified by the bone-targeting molecules, the nano material is loaded with the compound able to react with the acidic sealing zone in the osteoclasts. Through accurate mature osteoclast targeting and chemically regulated biocascade effects, the osteoclasts are inhibited, which provides a new idea and a new tool for drug therapy of abnormal osteoclast activation.

The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

The present invention relates to a method for producing polymersomes comprising a finalisation step using a dual centrifuge (DC) or a dual asymmetric centrifuge (DAC), polymersomes obtainable by said method and their use as a medicament.

In some aspects, the present invention provides heteroclitic CALRMUT peptides designed and selected to elicit an immune response to CALRMUT in subjects with JAK2 mutant-negative myeloproliferative neoplasms, nucleic acid molecules encoding such peptides, compositions comprising such peptides or nucleic acid molecules, and various associated compositions and methods.

A liposome for use in delivering a therapeutically active agent to a subject in need thereof is disclosed herein. The liposome comprises: a) at least one bilayer-forming lipid; b) a polymeric compound having the general formula I: ##STR00001## wherein m, n, L, X, Y, and Z are as defined herein; and c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome.

Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM, leading to widespread shutdown of vascular flow, hemorrhage, and necrosis. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors.